MedTrace Logo

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

NCT06550271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2024-08-13

No results posted yet for this study

Summary

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Conditions

  • Aging

Interventions

DRUG

Rapamycin

Rapamycin in 2 different dosage forms (compounded and generic)

Sponsors & Collaborators

  • AgelessRx

    lead INDUSTRY

Principal Investigators

  • Sajad Zalzala, MD · AgelessRx

Eligibility

Min Age
40 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-12-15
Completion
2023-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06550271 on ClinicalTrials.gov